UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 153

Sortiert nach

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2019-05, Vol.380 (20), p.1929-1940

2019

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

The New England journal of medicine, 2017-03, Vol.376 (11), p.1015-1026

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-10-18: Phyllodes tumor of the breast, clinicopathological features and prognostics factors in a retrospective cohort with 7-year follow-up

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-10-18

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-08-26: Outcomes and prognostic factors in 2000 patients with TNBC: Long-term results covering 10 years

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-08-26

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS2-05: Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS2-05-GS2-05

2019

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib-Thalidomide-Dexamethasone (VTD) As Salvage Treatment in Patients with Multiple Myeloma Candidates for Transplantation in the Real World

Blood, 2017, Vol.130, p.5427-5427

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-07-18: Breast cancer in young patients, twelve years of experience in a single institution

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-07-18

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-07-33: Impact of family history of breast and/or ovarian cancer in triple negative breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-07-33

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-10-11: Triple negative breast cancer in young Peruvian patients: 15-years' experience in a public hospital

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-10-11

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-15-06: Localized triple negative breast cancer in extremes of life

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-15-06

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-15-02: Benefit of adjuvant chemotherapy in disease-free survival for T1N0 triple negative breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-15-02

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-01-07: Comparison of the prognostic value of lymph node ratio versus residual lymph node status in triple negative breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-01-07

2018

Link zum Volltext

Verfügbarkeit prüfen

4535 POSTER Pronostic factors in seminoma

European journal of cancer supplements, 2007, Vol.5 (4), p.309-309

2007

Link zum Volltext

Verfügbarkeit prüfen

4540 POSTER Cyclophosphamide and cisplatin is an effective treatment in patients with stage II and III seminoma

European journal of cancer supplements, 2007, Vol.5 (4), p.310-310

2007

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for outcome in Hispanic patients with breast cancer with central nervous system (CNS) metastases

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e11523-e11523

2011

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effectiveness of a Barcelona Home Care Program for Individuals with Multimorbidity

Journal of the American Geriatrics Society (JAGS), 2015-05, Vol.63 (5), p.1017-1024

2015

Link zum Volltext

Verfügbarkeit prüfen

Responses rates and outcome to neoadjuvant chemotherapy in triple-negative breast cancers (TNBC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e11522-e11522

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of the ratio of positive axillary lymph node after neoadjuvant chemotherapy in Peruvian patients with breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e11521-e11521

2011

Link zum Volltext

Verfügbarkeit prüfen

A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS120-TPS120

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-12-26

2013

Link zum Volltext

Verfügbarkeit prüfen

HER2+ Tumors with Lack Steroid Receptors Showed a Shorter DFS but Similar OS Compared to HER2+ Tumors That Also Express ER and/or PR

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.6052-6052

2009

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for central nervous system (CNS) metastases in patients with stage I-III breast cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1063-1063

2010

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathologic, molecular subtype, and survival prognostic features in premenopausal breast cancer patients by age at diagnosis

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.653-653

2010

Link zum Volltext

Verfügbarkeit prüfen

Prognostic effect of hormone receptor status in early HER2-positive breast cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e11074-e11074

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(148)

Publikationsform

Artikel
(148)
Tagungsberichte
(5)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(47)
Life Sciences & Biomedicine
(34)
Oncology
(27)
Humans
(25)
Female
(18)
Breast Cancer
(17)
Middle Aged
(11)
Aged
(10)
Hematology, Oncology And Palliative Medicine
(9)
Adult
(8)
Chemotherapy
(8)
Male
(8)
Peru
(8)
Patients
(7)
Aged, 80 And Over
(6)
Breast Neoplasms - Drug Therapy
(6)
Cancer Therapies
(6)
Metastasis
(6)
Receptor, Erbb-2 - Genetics
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Abstract P6-10-18: Phyllodes tumor of the breast, clinicopathological features and prognostics factors in a retrospective cohort with 7-year follow-up

Abstract P6-08-26: Outcomes and prognostic factors in 2000 patients with TNBC: Long-term results covering 10 years

Abstract GS2-05: Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer

Bortezomib-Thalidomide-Dexamethasone (VTD) As Salvage Treatment in Patients with Multiple Myeloma Candidates for Transplantation in the Real World

Abstract P1-07-18: Breast cancer in young patients, twelve years of experience in a single institution

Abstract P1-07-33: Impact of family history of breast and/or ovarian cancer in triple negative breast cancer

Abstract P3-10-11: Triple negative breast cancer in young Peruvian patients: 15-years' experience in a public hospital

Abstract P1-15-06: Localized triple negative breast cancer in extremes of life

Abstract P1-15-02: Benefit of adjuvant chemotherapy in disease-free survival for T1N0 triple negative breast cancer

Abstract P3-01-07: Comparison of the prognostic value of lymph node ratio versus residual lymph node status in triple negative breast cancer

4535 POSTER Pronostic factors in seminoma

4540 POSTER Cyclophosphamide and cisplatin is an effective treatment in patients with stage II and III seminoma

Risk factors for outcome in Hispanic patients with breast cancer with central nervous system (CNS) metastases

Cost-Effectiveness of a Barcelona Home Care Program for Individuals with Multimorbidity

Responses rates and outcome to neoadjuvant chemotherapy in triple-negative breast cancers (TNBC)

Prognostic value of the ratio of positive axillary lymph node after neoadjuvant chemotherapy in Peruvian patients with breast cancer

A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801

Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)

HER2+ Tumors with Lack Steroid Receptors Showed a Shorter DFS but Similar OS Compared to HER2+ Tumors That Also Express ER and/or PR

Risk factors for central nervous system (CNS) metastases in patients with stage I-III breast cancer

Clinicopathologic, molecular subtype, and survival prognostic features in premenopausal breast cancer patients by age at diagnosis

Prognostic effect of hormone receptor status in early HER2-positive breast cancer

Suchergebnisse filtern